65,437 trials
Systemic Lupus Erythematosus
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) Through Week 52 — 0; 0; 2; 0 Participants
Anxiety Disorders · Depression · Posttraumatic Stress Disorder
Primary: Change in Cognitive Performance — 4.92; 8.18; .27 score on a scale
Asthma in Children · Obesity · Obesity, Adolescent
Primary: Number of Participants Completing 4-week Study Period — 10; 11 Participants
Influenza, Human
Primary: Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs) — 0; 2; 2; 2 Participants
Alcohol Use Disorder · Alcohol Misuse
Primary: Weekly Percentage of Heavy Drinking Days — 51.5; 52.9 percentage of days per week
Chronic Low-back Pain
Primary: Patient-Reported Pain Intensity and Interference Score — 4.16; 3.86; 3.57; 4.72 score on a scale
Influenza, Human · COVID-19
Primary: SSA: Percentage of Participants With Local Reactions up to 7 Days Following Vaccination (18-64 Years) — 83.3; 89.3; 80.0; 63.3 Percentage of participants
Prostate Cancer
Primary: Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study — 95.0 percentage of participants
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
HIV
Primary: PrEP Interest (Peer-Recruit Participants) — 2; 3 Participants
Postpartum · Women · Community Health Workers
Primary: Knowledge Pretest Score — 77.08; 80.19 score on a scale — p=0.32
Healthy Aging · Alzheimer Disease
Primary: Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Metabolism (Standard Uptake Value Ratio) — -0.0514; -0.0667 SUVR
Other Instability, Ankle and Foot
Primary: Dynamic Balance: (Star Excursion Balance Test) — 72.3; 78.0 % of leg length
Mantle-Cell Lymphoma
Primary: Progression-Free Survival (PFS) — 8 years